Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus PROCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus PROCAINE HYDROCHLORIDE.
LIDOSITE TOPICAL SYSTEM KIT vs PROCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Blocks voltage-gated sodium channels, inhibiting nerve impulse conduction by stabilizing the neuronal membrane and preventing depolarization.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
Local infiltration: 0.5% solution, up to 200 mg (40 mL) per dose. Nerve block: 0.5% solution, 100-200 mg (20-40 mL) per dose. Intravenous regional anesthesia (Bier block): 0.5% solution, 50-100 mg (10-20 mL) per dose. Maximum total dose: 200 mg without epinephrine, 250 mg with epinephrine 1:200,000.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal elimination half-life is approximately 7.7 minutes in adults with normal hepatic function. This short half-life reflects rapid hydrolysis by plasma pseudocholinesterases. In patients with pseudocholinesterase deficiency, half-life may be prolonged to 20-30 minutes.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Primarily renal excretion of metabolites (para-aminobenzoic acid and diethylaminoethanol) and unchanged drug. Approximately 80% of a dose is excreted in urine as para-aminobenzoic acid and conjugates; <2% excreted unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic